Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more
Market Cap & Net Worth: Hainan Huluwa Pharmaceutical Group Co Ltd (605199)
Hainan Huluwa Pharmaceutical Group Co Ltd (SHG:605199) has a market capitalization of $371.90 Million (CN¥2.73 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #16857 globally and #4438 in its home market, demonstrating a -0.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hainan Huluwa Pharmaceutical Group Co Ltd's stock price CN¥6.82 by its total outstanding shares 400108752 (400.11 Million).
Hainan Huluwa Pharmaceutical Group Co Ltd Market Cap History: 2020 to 2026
Hainan Huluwa Pharmaceutical Group Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $1.31 Billion to $371.90 Million (-1.50% CAGR).
Hainan Huluwa Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hainan Huluwa Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.61x
Hainan Huluwa Pharmaceutical Group Co Ltd's market cap is 0.61 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.31 Billion | $1.16 Billion | $121.50 Million | 1.13x | 10.77x |
| 2021 | $1.36 Billion | $1.35 Billion | $72.14 Million | 1.00x | 18.84x |
| 2022 | $873.59 Million | $1.52 Billion | $85.68 Million | 0.58x | 10.20x |
| 2023 | $826.69 Million | $1.80 Billion | $106.50 Million | 0.46x | 7.76x |
| 2024 | $868.68 Million | $1.41 Billion | -$274.46 Million | 0.61x | N/A |
Competitor Companies of 605199 by Market Capitalization
Companies near Hainan Huluwa Pharmaceutical Group Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Hainan Huluwa Pharmaceutical Group Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hainan Huluwa Pharmaceutical Group Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Hainan Huluwa Pharmaceutical Group Co Ltd's market cap moved from $1.31 Billion to $ 371.90 Million, with a yearly change of -1.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥371.90 Million | -10.50% |
| 2025 | CN¥415.53 Million | -52.17% |
| 2024 | CN¥868.68 Million | +5.08% |
| 2023 | CN¥826.69 Million | -5.37% |
| 2022 | CN¥873.59 Million | -35.71% |
| 2021 | CN¥1.36 Billion | +3.87% |
| 2020 | CN¥1.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hainan Huluwa Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $371.90 Million USD |
| MoneyControl | $371.90 Million USD |
| MarketWatch | $371.90 Million USD |
| marketcap.company | $371.90 Million USD |
| Reuters | $371.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.